New agents for treating dry eye syndrome
Related Experiment Video
Updated: May 17, 2026

Establishment of A Mouse Model of Aqueous Deficiency Dry Eye
Published on: November 1, 2024
Simon E Skalicky1, Con Petsoglou, Avinash Gurbaxani
1Save Sight Institute, University of Sydney, Sydney, NSW, Australia. seskalicky@gmail.com
Abstract:
Dry eye syndrome (DES) is characterized by an inadequate volume and/or quality of tears resulting in chronic ocular surface irritation and inflammation. Affecting up to 30 % of adults, DES has a considerable impact on visual function and quality of life. DES may complicate allergic ocular disease and allergy medication may exacerbate DES. The pathophysiology of DES involves osmotic, mechanical and inflammatory insults to the tear film, epithelium and subepithelial nerve plexus. Various immune-related molecular targets have been the focus of research aimed at developing new therapeutic agents for treating DES. This article provides an overview of established, new and future agents for treating DES.
Related Concept Videos
Ophthalmic Drug Delivery Systems
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Glaucoma: Overview
Local Anesthetics: Common Agents and Their Applications
Cocaine is an ester of benzoic acid and methylecgogine. It is used to anesthetize and vasoconstrict locally. Currently, it is used primarily for topical applications. It is beneficial for surgeries on the upper respiratory tract, providing anesthesia and shrinking the mucosa. Cocaine in the form of cocaine hydrochloride is...
